To assess the feasibility and safety of phased withdrawal of guideline-directed medical therapy (GDMT) in patients with heart failure and improved ejection fraction following successful atrial fibrillation catheter ablation.
Approach:
Study Design: An open-label, parallel-group pilot randomized clinical trial conducted at Beijing Anzhen Hospital from April 2023 to September 2024.
Inclusion and Exclusion Criteria: Inclusion criteria included patients aged 18-80 years, 3 months post-ablation, LVEF improvement, and absence of HF symptoms. Exclusion criteria included other cardiomyopathies, uncontrolled hypertension, and significant coronary artery disease.
Randomization and Treatment: Eligible patients were randomized 1:1 to either phased GDMT withdrawal or continuation, with a follow-up period of 6 months.
Withdrawal Protocol: In the withdrawal group, medications were reduced stepwise every 2 weeks, with specific protocols for various medications.
Follow-Up Assessments: Patients underwent clinical assessments, NT-proBNP analysis, echocardiography, and KCCQ-12 scoring at baseline and follow-up.
Key Findings:
The study aims to evaluate the safety of GDMT withdrawal in patients with improved cardiac function post-ablation.
The primary endpoint is defined as HF deterioration within 6 months based on specific echocardiographic and NT-proBNP criteria.
Interpretation:
The study aims to clarify the long-term management of HF medications in patients with improved cardiac function after AF treatment.
Limitations:
The study is a pilot trial, which may limit generalizability.
The sample size and duration may not provide definitive conclusions regarding safety and efficacy.
Conclusion:
The trial will provide insights into the management of HF medications in patients with improved cardiac function following AF treatment.
